Skip to the main content.
Facebook Instagram Linkedin X YouTube Medium

megamenu-services

 

Turn Vision into Velocity with the Innovation CRO

Traditional CROs fragment device development with costly hand-offs and learning curves. Veranex unites the essential disciplines for medical device & diagnostic development under one roof from sketch to evidence-generation to market launch.

All connected. All aligned. All accelerating your path to market—delivering breakthrough devices and diagnostics that improve patient lives sooner.

Explore our Services

megamenu-solutions-expertise

 

Outcome-Driven Solutions for Medtech Challenges

Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.

Purpose-built solutions. Proven results. User & Patient-centered innovation.

 

Solutions

Expertise

megamenu-company-2

 

Purpose-Built for Breakthroughs

Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity.  Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.  

We are the Innovation CRO.

Legacy of excellence. Proven execution. Patient impact accelerated.

 

Explore our Company

Build, Buy, or Partner: Master Medtech M&A and Innovation Strategy

Medtech M&A & portfolio strategists blend technology landscaping, reimbursement and cross‑functional due diligence—so you have full line‑of‑sight on technical, clinical, and economic risk.

Why Traditional M&A Playbooks Fall Short in Medtech

Medical device mergers and acquisitions (Medtech M&A) hinge on hidden variables that go far beyond headline deal multiples—FDA 510(k), De Novo, or PMA routes; EU MDR/IVDR and UK CA clearances; engineering feasibility; coding timelines; and payer economics that differ by region and care setting. Miss just one, and a nine-figure acquisition can bleed value before the first integration workshop. Veranex unites Product Design & Engineering, Clinical/Regulatory, HEOR, and Market-Access experts to surface those risks early—then turn them into strategic levers that accelerate post-close growth.
ma-model

Innovation-to-Value Framework for Medtech M&A & Portfolio Strategy

Smart deals and high-return pipelines share the same DNA: clear market demand, feasible technology, and proven reimbursement pathways. Our framework layers those checks—technical diligence, EU MDR/IVDR and FDA route mapping, price-elasticity modeling—onto every target and asset, letting you compare medical device M&A options and portfolio candidates side-by-side.

The result: faster yes/no decisions, de-risked investments, and capital redeployed toward the highest-value innovations.
Pillar What we deliver Your advantage

Portfolio & Pipeline Prioritization

Tech landscaping, care pathway analysis, evidence gap assessment, risk adjusted NPV scoring.

Invest where clinical need, reimbursement feasibility, and market upside intersect.

Buy Build Partner Analysis

Gap mapping, scenario models for organic vs. inorganic growth.

Choose the fastest, most cost effective route to category leadership.

M&A & Due Diligence Support

Technical, regulatory, and medical device M&A reimbursement diligence; supplier audits; PMI roadmaps.

De risk deals and accelerate post close value capture.

Innovation Capability & Learning Programs

Stage gate redesign, venture boards, precision medicine and access workshops.

Embed a repeatable innovation engine inside your organization.

Engage Us When You Need Clarity

Whether you’re triaging a crowded pipeline, scouting acquisition targets, or racing to integrate a new asset, our cross‑functional pods plug in quickly, leverage agile sprints for rapid insight, and hand you a dashboard that tracks deal value from Day 1 through post‑close execution.

Services Overview

Medtech M&A & Growth Service Modules: Deploy What Fits

A fast-moving market means yesterday’s portfolio map can be tomorrow’s blind spot. Our medical device M&A and growth team closes that gap by fusing real-time technology landscaping, reimbursement feasibility, and risk-adjusted NPV scoring into one decision engine. Whether you’re screening targets for a medical device merger or acquisition, triaging an overgrown R&D slate, or sizing up a critical “buy-build-partner” call, we surface the technical, clinical, and economic signals that matter—so capital flows to the highest-value assets and deals de-risk before Day 1.

Portfolio Scoring Matrix

Portfolio Scoring Matrix

Prioritize assets and portfolio by market opportunity, reimbursement feasibility, and tech readiness.

ma-1

Technology & Market Landscaping

Technology & Market Landscaping

See who is developing technologies and global market opportunities pathway before you invest. 

ma-2

Clinical, Quality, & Reimbursement Due Diligence

Clinical, Quality, & Reimbursement Due Diligence

Uncover hidden submission, quality, coding, and payment risks that sink device deals.

ma-3

Innovation Capability Workshops

Innovation Capability Workshops

Equip teams with frameworks to scout, vet, and integrate new tech—repeatedly.

ma-4

Related Articles

Latest Blog Entries

Meet the Team

Your Medical Device M&A and Innovation Leadership

Benefit from a rare blend of scientific, founder, and M&A expertise to de-risk your investment and accelerate growth. 
cinzia

Cinzia Metallo, PhD 

Director, Product Commercialization
joe-gordon

Joe Gordon

Vice President, Innovation & Technology

Medtech M&A & Portfolio Strategy: Real-World Impact

See how our integrated due-diligence and growth playbooks turn complex deals into accelerated value.

ma-case-1

End-to-End Medtech M&A Support 

 

Situation

A global med-tech sponsor was pursuing a mid-market acquisition but lacked the internal bandwidth to handle target selection, due diligence, and post-close integration. They needed a partner that could scale resources quickly while acting as an extension of the core deal team.

Successes

  • Ramped specialized FTEs at peak activity, then tapered post-close.
  • Completed target identification, risk-based due diligence, and deal-structure support on schedule.
  • Our experts continued through the first 12 months to monitor performance and optimize integration, ensuring continuity and knowledge transfer.
  • Veranex operated “as an integrated part of our corporate development arm,” accelerating time-to-value.

 

Services by Veranex

  • Target Identification, Profiling, and Prioritization
  • Pre-Acquisition Planning
  • Technical, RAQA, & Reimbursement Due Diligence
  • Performance Monitoring & Post-Acquisition Integration

Discover More

Related Services at Veranex

Integrated Evidence Planning (IEP)

Integrated Evidence Planning (IEP)

Align studies that power payer acceptance pre- and post-deal

Learn more

Integrated_Evidence_Planning_500x500

Market Access & Reimbursement

Market Access & Reimbursement

Understand feasibility and secure codes and coverage for newly acquired assets.

Learn more

Pricing and Reimbursement_500x500

Product Design & Development – Research & Strategy

Product Design & Development – Research & Strategy

Turn insights into patient‑ready concepts.

Learn more

Research and Strategy_500x500

Book a 30 Minute Innovation or M&A Strategy Call

Make every buy-build-partner move data-driven with Veranex’s innovation and medtech M&A strategists—faster, smarter, fully de-risked.

Innovate with Veranex